Kura Oncology Inc - ESG Rating & Company Profile powered by AI
Check the end of the webpage for potential risks for Kura Oncology Inc based on industry, location and size. This ESG score includes 17 UN Sustainable Development Goals including: 'Gender Equality', 'Industry, Innovation & Infrastructure' and 'Partnerships for the Goals'. This assessment of Kura Oncology Inc incorporates information from across the internet as well as from available filings by Kura Oncology Inc.
Kura Oncology Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.9; made up of an environmental score of 8.0, social score of 4.8 and governance score of 8.0.
6.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 290 | Qiagen NV | 7.0 | High |
| 290 | WuXi AppTec Co Ltd | 7.0 | High |
| 294 | Kura Oncology Inc | 6.9 | High |
| 294 | Cabaletta Bio Inc | 6.9 | High |
| 294 | Bicycle Therapeutics PLC | 6.9 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Kura Oncology Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Kura Oncology Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Kura Oncology Inc report the average age of the workforce?
Sign up for free to unlockDoes Kura Oncology Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Kura Oncology Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Kura Oncology Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Kura Oncology Inc offer flexible work?
Sign up for free to unlockDoes Kura Oncology Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Kura Oncology Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Kura Oncology Inc conduct supply chain audits?
Sign up for free to unlockDoes Kura Oncology Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Kura Oncology Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Kura Oncology Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Kura Oncology Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Kura Oncology Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Kura Oncology Inc disclose water use targets?
Sign up for free to unlockDoes Kura Oncology Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Kura Oncology Inc have a product recall in the last two years?
Sign up for free to unlockDoes Kura Oncology Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Kura Oncology Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Kura Oncology Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Kura Oncology Inc disclose parental leave metrics?
Sign up for free to unlockDoes Kura Oncology Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Kura Oncology Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Kura Oncology Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Kura Oncology Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Kura Oncology Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Kura Oncology Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Kura Oncology Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Kura Oncology Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Kura Oncology Inc disclose its waste policy?
Sign up for free to unlockDoes Kura Oncology Inc report according to TCFD requirements?
Sign up for free to unlockDoes Kura Oncology Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Kura Oncology Inc disclose energy use targets?
Sign up for free to unlockDoes Kura Oncology Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Kura Oncology Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Kura Oncology Inc
These potential risks are based on the size, segment and geographies of the company.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.